<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273594</url>
  </required_header>
  <id_info>
    <org_study_id>CP-100-008</org_study_id>
    <nct_id>NCT04273594</nct_id>
  </id_info>
  <brief_title>FemBlocÂ® Permanent Contraception - Confirmation Feasibility Trial</brief_title>
  <acronym>BLOC</acronym>
  <official_title>BLOC: Prospective, Multi-Center, Study of Subjects Undergoing FemBloc Permanent Contraception With Two Confirmation Procedures (FemBloc With FemChec and Fluoro HSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Femasys Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Femasys Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial objectives include evaluating the adequacy of proposed mitigations for the previous&#xD;
      pivotal trial of the FemBloc Permanent Contraceptive System and validating the confirmation&#xD;
      procedure by comparing FemChec (ultrasound) to fluoroscopic hysterosalpingogram (fluoro HSG)&#xD;
      for post-occlusion in the same patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reliance Rate</measure>
    <time_frame>within 1 year</time_frame>
    <description>Number of subjects told to rely divided by number of qualified subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance</measure>
    <time_frame>within 1 year</time_frame>
    <description>Concordance between FemBloc confirmation with FemChec and Fluoro HSG confirmation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>FemBloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational device and procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FemBloc</intervention_name>
    <description>Treatment with FemBloc for women who desire permanent birth control (female sterilization)</description>
    <arm_group_label>FemBloc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, 21 - 45 years of age desiring permanent birth control&#xD;
&#xD;
          -  Sexually active with male partner&#xD;
&#xD;
          -  Regular menstrual cycle for last 3 months or on hormonal contraceptives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncertainty about the desire to end fertility&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Prior tubal surgery, including sterilization attempt&#xD;
&#xD;
          -  Prior endometrial ablation&#xD;
&#xD;
          -  Presence, suspicion, or previous history of gynecologic malignancy&#xD;
&#xD;
          -  Abnormal uterine bleeding requiring evaluation or treatment&#xD;
&#xD;
          -  Scheduled to undergo concomitant intrauterine procedures at the time of procedure(s)&#xD;
&#xD;
          -  Allergy to shellfish, betadine or iodinated contrast&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>770-500-3910</phone>
    <phone_ext>146</phone_ext>
    <email>studysupport@femasys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Precision Trials AZ, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals - Cleveland Medical Center</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>permanent contraception</keyword>
  <keyword>birth control</keyword>
  <keyword>pregnancy prevention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

